Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 5, Pages 661-668Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.5.661
Keywords
Gram-negative bacteria; multidrug-resistance; polymyxin B
Categories
Ask authors/readers for more resources
Background: There has been a renewed interest in using polymyxin B as a last resort therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite being available for clinical use for decades, there is still a very limited understanding on many aspects of this agent. Objective: To review what is known about polymyxin B and to identify missing information or gaps for future investigations. Methods: Pertinent information was reviewed from published literature in English. Results/conclusion: For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available